# Aclarion Announces Inducement Grant to New Commercial Director, Western U.S.
Canonical URL: https://biopharmsignal.com/news/ACON/aclarion-announces-inducement-grant-to-new-commercial-director-western-u-s-12ab02a1
Ticker: ACON
Company: Aclarion
Source: Aclarion
Published: 2026-05-06 10:00 EST
## Summary

Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and prop...

## Article Body
Aclarion, Inc. , (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms through its Nociscan® platform to help physicians identify the location of chronic low back pain and support improved treatment success rates, today announced that the compensation committee of Aclarion’s board of directors granted Daniel Keefe, the Company's recently-hired Commercial Director, Western U.S., an inducement stock option to purchase an aggregate of 17,000 shares of Aclarion's common stock on May 5, 2026. This stock option was agreed to as an inducement material to Mr. Keefe entering into employment with Aclarion. The option was agreed to and granted in accordance with Nasdaq Listing Rule 5635(c)(4).

The option has an exercise price of $3.20 per share, which was equal to the closing price of Aclarion's common stock on the grant date. One-fourth of the options vest on the one-year anniversary of the vesting commencement date, and the remainder vest in equal monthly installments over the next three years, subject to the new employee's continued service with the Company. The stock option has a 10-year term and is subject to the terms and conditions of an inducement stock option agreement covering the grant.

About Aclarion, Inc.

Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com .

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. Forward-looking statements in this release include, among others, statements regarding the increasing demand for Nociscan. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contacts:

Kirin M. Smith PCG Advisory, Inc. ksmith@pcgadvisory.com

Media Contacts:

Jennie Kim SPRIG Consulting jennie@sprigconsulting.com
## Recent Company News
- 2026-07-21 11:00 EST — [Aclarion Announces Presentation of Two Abstracts Highlighting Nociscan’s Growing Role in Real-World Clinical Practice](https://biopharmsignal.com/news/ACON/aclarion-announces-presentation-of-two-abstracts-highlighting-nociscan-s-growing-2363a199) — Source: Aclarion
- 2026-07-07 11:00 EST — [Aclarion Announces Texas Spine Care Center as New CLARITY Site](https://biopharmsignal.com/news/ACON/aclarion-announces-texas-spine-care-center-as-new-clarity-site-e1c30414) — Source: Aclarion
- 2026-06-10 11:00 EST — [Aclarion to Present at the Planet MicroCap Las Vegas Powered by MicroCapClub](https://biopharmsignal.com/news/ACON/aclarion-to-present-at-the-planet-microcap-las-vegas-powered-by-microcapclub-87cbf66e) — Source: Aclarion
- 2026-06-09 11:00 EST — [Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform](https://biopharmsignal.com/news/ACON/aclarion-partners-with-pria-healthcare-to-advance-reimbursement-and-commercial-a-730b08c0) — Source: Aclarion
- 2026-06-08 11:05 EST — [Aclarion Rejects Echo Lake Capital’s Unsolicited Acquisition Proposal](https://biopharmsignal.com/news/ACON/aclarion-rejects-echo-lake-capital-s-unsolicited-acquisition-proposal-fc44ebdb) — Source: Aclarion
## Related News
- 2026-07-29 20:05 EST — SERA — [SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF SECOND QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON AUGUST 12, 2026](https://biopharmsignal.com/news/SERA/sera-prognostics-announces-conference-call-and-webcast-of-second-quarter-fiscal--2a2c0c5a)
- 2026-07-29 20:05 EST — VKTX — [Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/VKTX/viking-therapeutics-reports-second-quarter-2026-financial-results-and-provides-c-2f09b8ce)
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)